Versant Venture Capital VI, L.P. 13D/13G Filings for Black Diamond Therapeutics, Inc. (BDTX)

Versant Venture Capital VI, L.P. 13D and 13G filings for Black Diamond Therapeutics, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime
Transaction
Date
TypeCompany
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev ReportView
2024-08-08
4:48 pm
Unchanged
2024-08-0613DBlack Diamond Therapeutics, Inc.
BDTX
Versant Venture Capital VI, L.P.4,328,883
7.700%
0
(Unchanged)
Filing
2023-11-09
5:24 pm
Unchanged
2023-08-1113DBlack Diamond Therapeutics, Inc.
BDTX
Versant Venture Capital VI, L.P.4,328,883
8.400%
0
(Unchanged)
Filing